TY - JOUR
T1 - Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors
AU - Schoenbeck, Kelly L.
AU - Atallah, Ehab
AU - Lin, Li
AU - Weinfurt, Kevin P.
AU - Cortes, Jorge
AU - Deininger, Michael W.N.
AU - Kota, Vamsi
AU - Larson, Richard A.
AU - Mauro, Michael J.
AU - Oehler, Vivian G.
AU - Pinilla-Ibarz, Javier
AU - Radich, Jerald P.
AU - Schiffer, Charles A.
AU - Shah, Neil P.
AU - Silver, Richard T.
AU - Thompson, James E.
AU - Flynn, Kathryn E.
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.
AB - Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual function were assessed over 36 months in 172 adult patients with chronic phase CML from 14 sites at baseline (on TKI) and after discontinuation. Linear mixed-effects models described the average trajectories for each patient-reported outcome measure after discontinuation and in those who restarted TKI. Of 112 patients in TFR at 12 months, 103 (92.0%) had a 3-point or greater improvement in social function, 80 (71.4%) in social isolation, 11 (9.8%) in satisfaction with sex life, 4 (3.6%) in physical function, and no patients had a 3-point or greater improvement in cognitive function or interest in sexual activity. Patients' scores worsened after restarting TKI. This novel information on functional outcomes in TFR can help guide patient and clinician decision making.
UR - http://www.scopus.com/inward/record.url?scp=85123645552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123645552&partnerID=8YFLogxK
U2 - 10.1093/jnci/djab184
DO - 10.1093/jnci/djab184
M3 - Article
C2 - 34491344
AN - SCOPUS:85123645552
SN - 0027-8874
VL - 114
SP - 160
EP - 164
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 1
ER -